Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts

Novartis upped its 2019 forecast for its generics business, Sandoz, but Wall Street analysts worry that price erosion in the U.S. is taking more of a toll on the company than it is on its competitors.